Abstract
Adenine nucleotides, ADP and ATP, are coreleased from dense granules during platelet activation, as well as from endothelial cells and damaged red blood cells following vascular injury. Through autocrine and paracrine mechanisms, these extracellular signaling molecules interact with the platelet P2 receptors to amplify ongoing platelet activation. Two receptors for ADP, the Gq-protein-coupled P2Y1 and Gi-protein-coupled P2Y12 and one receptor for ATP, the P2X1 ion channel, have been identified on platelets. Due to distinct pharmacological properties and differential regulation, the P2Y and P2X receptors essentially operate on different scales of time and distance and trigger selective intracellular signaling cascades. Recent advances in the understanding of the P2Y receptor physiology have reinforced the concept of these receptors as useful targets for antithrombotic therapy. The function of P2X1 in platelet activation only recently started to be unraveled. This review focuses on recent findings on the physiology of these platelet ADP and ATP receptors, their distinct downstream intracellular signaling pathways as well as on the available agonists, antagonists and inhibitors that allow their pharmacological discrimination.
Keywords: Hemostasis, thrombosis, adenine nucleotides, P2Y1, P2Y12, P2X1, antithrombotic therapy
Current Pharmaceutical Design
Title: The Platelet ATP and ADP Receptors
Volume: 12 Issue: 7
Author(s): C. Oury, E. Toth-Zsamboki, J. Vermylen and M. F. Hoylaerts
Affiliation:
Keywords: Hemostasis, thrombosis, adenine nucleotides, P2Y1, P2Y12, P2X1, antithrombotic therapy
Abstract: Adenine nucleotides, ADP and ATP, are coreleased from dense granules during platelet activation, as well as from endothelial cells and damaged red blood cells following vascular injury. Through autocrine and paracrine mechanisms, these extracellular signaling molecules interact with the platelet P2 receptors to amplify ongoing platelet activation. Two receptors for ADP, the Gq-protein-coupled P2Y1 and Gi-protein-coupled P2Y12 and one receptor for ATP, the P2X1 ion channel, have been identified on platelets. Due to distinct pharmacological properties and differential regulation, the P2Y and P2X receptors essentially operate on different scales of time and distance and trigger selective intracellular signaling cascades. Recent advances in the understanding of the P2Y receptor physiology have reinforced the concept of these receptors as useful targets for antithrombotic therapy. The function of P2X1 in platelet activation only recently started to be unraveled. This review focuses on recent findings on the physiology of these platelet ADP and ATP receptors, their distinct downstream intracellular signaling pathways as well as on the available agonists, antagonists and inhibitors that allow their pharmacological discrimination.
Export Options
About this article
Cite this article as:
Oury C., Toth-Zsamboki E., Vermylen J. and Hoylaerts F. M., The Platelet ATP and ADP Receptors, Current Pharmaceutical Design 2006; 12 (7) . https://dx.doi.org/10.2174/138161206776056029
DOI https://dx.doi.org/10.2174/138161206776056029 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antenatal Glucocorticoids Supplementation and Central Nervous System Development
Current Drug Metabolism Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Lifestyle Factors and Endothelial Function
Current Vascular Pharmacology Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor
Current Cardiology Reviews The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Blood Pressure Variability and Mortality in end Stage Renal Disease
Current Hypertension Reviews Biophysical Modeling and Associated Signal Modeling in Functional Magnetic Resonance Imaging
Neuroscience and Biomedical Engineering (Discontinued) Multi-Constituent Cardiovascular Pills (MCCP) - Challenges and Promises of Population-Based Prophylactic Drug Therapy for Prevention of Heart Attack
Current Pharmaceutical Design The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Current Pharmaceutical Design Platelets in Atherothrombosis: New and Evolving Roles
Current Pharmaceutical Design The Biological Effects of Diagnostic Cardiac Imaging
Current Pharmaceutical Design Therapeutic Potential of Endothelial Progenitor Cells in the Field of Orthopaedics
Current Stem Cell Research & Therapy Applications of Arterial Spin Labelling in Mild Cognitive Impairment, Alzheimers Disease and Other Forms of Dementia
Current Medical Imaging Cocaine Dependence and Stroke: Pathogenesis and Management
Current Neurovascular Research Empowering Translational Research in Fetal Growth Restriction: Sheep and Swine Animal Models
Current Pharmaceutical Biotechnology Resveratrol and Cardiovascular Disease
Current Nutrition & Food Science Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Breastfeeding and Diabetes
Current Diabetes Reviews Functional and Structural Alterations of Large Arteries: Methodological Issues
Current Pharmaceutical Design Heart Failure and Diabetes: Perspective of a Dangerous Association
Current Hypertension Reviews